| Diane M Karl, MD | |
|
5050 Ne Hoyt St, Suite 317, Portland, OR 97213-2991 | |
| (503) 256-4096 | |
| (503) 256-0101 |
| Full Name | Diane M Karl |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 54 Years |
| Location | 5050 Ne Hoyt St, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891797346 | NPI | - | NPPES |
| 128236 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD18768 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Endocrine Clinic Pc | 1850363003 | 4 |
News Archive
Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.
Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.
Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.
› Verified 4 days ago
| Entity Name | The Endocrine Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255367884 PECOS PAC ID: 1850363003 Enrollment ID: O20040809001305 |
News Archive
Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.
Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.
Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diane M Karl, MD 5050 Ne Hoyt St, Suite 317, Portland, OR 97213-2991 Ph: (503) 256-4096 | Diane M Karl, MD 5050 Ne Hoyt St, Suite 317, Portland, OR 97213-2991 Ph: (503) 256-4096 |
News Archive
Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.
Using technology that makes it possible to zoom in on smaller sections of cell chromosomes than ever before, researchers at Dana-Farber Cancer Institute have identified nearly 100 chromosome regions where genes are either over-copied or missing in non-small cell lung cancer.
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.
Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.
› Verified 4 days ago
Salona Shrestha, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |